Doug Ingram, Sarepta CEO
September 13, 2022 06:19 AM EDT
Financing

Eye­ing ac­cel­er­at­ed ap­proval for Duchenne gene ther­a­py, Sarep­ta hopes to bring in $1B in bid for prof­itabil­i­ty

Lei Lei Wu

News Reporter

On Mon­day, Al­ny­lam an­nounced that it was look­ing to raise $900 mil­lion on the back of a pos­i­tive read­out for its drug in AT­TR …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

Eli Lil­ly stock­piles $548M of oral weight loss drug ahead of launch

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times